

EVALUATION OF PROLACTIN TEST ORDERING PRACTICES

MC. Rabah (1), D. Zouari (1), R. Marrakchi (1), M. Boudaya (1), K. Jamoussi (1), M. Abid (2), M. Turki (1)

- (1) Laboratory of Biochemistry, Hédi-Chaker Hospital, Sfax, Tunisia
 (2) Endocrinology department, Hédi-Chaker Hospital, Sfax, Tunisia

Introduction

Hyperprolactinemia can be caused by physiological changes, medications, pathological conditions, or can be idiopathic.

Aim: The aim of this study was to evaluate clinicians' practice in ordering prolactin (PRL) tests.

- Mean PRL level : 27 (1,8-196,15) years

⇒ Among requests with clinical indications of having hyperprolactinemia and requests without clinical indications, only 29.4%, and 28.6% had respectively hyperprolactinemia.

Methods

- A retrospective study during January 2024
- Seventy five (75) prolactin requests
- Data were collected by the laboratory computer system (Health Lab)
- We collected age, sex and ordering origins
- Cortisol tests were performed based on electrochemiluminescence immunoassay (eCLIA) by Dxi600® Beckman Coulter
- Hyperprolactinemia was defined by PRL levels above 25ng/ml and 15 ng/ml respectively for women and for men.

Discussion

In our study, the early age of onset of hyperprolactinemia is related to the underlying etiology, which is consistent with the literature. [1]

However, our results showed lower etiology-related rates compared to various studies, which may be attributed to the small sample size and the retrospective nature of our study. [2,3,4]

Results

- Mean Age : 37 (13-85) years
- Sex-ratio (M/F) : de 0,3
- Requesting departments : PRL requests were from the endocrinology department (58.7%), followed by the gynecology department (18.7%) and the psychiatry department (13.3%)
- Reasons for prescribing a PRL test : (Fig 1)




Fig. 1: Indications for Prescribing a PRL Test

⇒ 37.3% of the requests were without clinical indications

Bibliography

1. Khelifi, A., & Latrech, H. (2017). Profil clinique et étiologique de l'hyperprolactinémie chez la femme au CHU Mohammed VI Oujda. *Annales d'Endocrinologie*, 78(4), 315.
2. Smith, T. P., Kavanagh, L., Healy, M.-L., & McKenna, T. J. (2007). *Technology Insight: measuring prolactin in clinical samples. Nature Clinical Practice Endocrinology & Metabolism*, 3(3), 279–289. doi:10.1038/ncpendmet0447
3. Mah, P. M., & Webster, J. (2002). *Hyperprolactinemia: Etiology, Diagnosis, and Management. Seminars in Reproductive Medicine*, 20(4), 365–374. doi:10.1055/s-2002-36709
4. Lee, D.-Y., Oh, Y.-K., Yoon, B.-K., & Choi, D. (2012). Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. *American Journal of Obstetrics and Gynecology*, 206(3), 213.e1–213.e5.